The National Academies Logo
Research Associateship Programs
Fellowships Office
Policy and Global Affairs

Participating Agencies - NIST

Opportunity at National Institute of Standards and Technology (NIST)

Analytical Metrology for Quantifying Drug Release Profiles from Nanotechnology-Enabled Medical Products

Location

Material Measurement Laboratory, Biosystems and Biomaterials Division

RO# Location
50.64.41.C0326 Gaithersburg, MD

Please note: This Agency only participates in the February and August reviews.

Advisers

Name E-mail Phone
Nelson, Bryant C. bryant.nelson@nist.gov 301.975.2517
Petersen, Elijah Joel elijah.petersen@nist.gov 301.975.8142

Description

The use and application of vectors such as liposomes, nanocrystals and/or emulsions for the delivery of nucleic acid, protein and/or small molecule therapeutics in nanotechnology-enabled drug products has steadily and rapidly increased over the last 2 decades.[1] However, corresponding development of robust and reproducible in vitro assays for evaluating the critical quality attributes and/or the biological responses of these nano-enabled drug products in biorelevant media has not kept pace with the development of new drug products nor with the evolution of generic drug products.[2,3] Specifically, in vitro assays focused on the quantitative assessment and molecular-scale characterization of free drug released from vector encapsulated drug are of prime importance for quality assessments and regulatory approval of drug products. Pharmaceutical manufacturers typically use in vitro assays on new encapsulations to assess drug availability, to monitor quality control and/or to fulfill regulatory requirements. Current versions of in vitro drug release assays are generally time consuming, complex and non-standardized. There exists a critical need to develop in vitro assays that are robust and reproducible. This research opportunity entails the design, development and controlled evaluation of in vitro drug release assays that are capable of accurate temporal measurement of free, protein-bound and vector-encapsulated drug fractions in nano-enabled drug products. Assay development efforts should focus on the incorporation of a robust and optimized experimental design aimed at assessing the sources of variability, repeatability and reproducibility of the assay. Assay measurements should incorporate the use of process controls, rigorous statistical analysis techniques and assay robustness evaluations appropriate for the design of interlaboratory studies.

References
(1) D'Mello, S. R.; Cruz, C. N.; Chen, M. L.; Kapoor, M.; Lee, S. L.; Tyner, K. M. Nat Nanotechnol 2017, 12, 523-529.
(2) Coty, J. B.; Vauthier, C. J Control Release 2018, 275, 254-268.
(3) Gioria, S.; Caputo, F.; Urban, P.; Maguire, C. M.; Bremer-Hoffmann, S.; Prina-Mello, A.; Calzolai, L.; Mehn, D. Nanomedicine-Uk 2018, 13, 539-554.

Keywords:
Drug delivery; Drug product; Drug release; Exosomes; In vitro assays; Liposomes; Measurement assurance; Medical; Method development; Nanomedicine; Nanotechnology; Pharmaceutical

Eligibility

Citizenship:  Open to U.S. citizens
Level:  Open to Postdoctoral applicants

Stipend

Base Stipend Travel Allotment Supplementation
$72,028.00 $3,000.00
Copyright © 2014. National Academy of Sciences. All rights reserved. 500 Fifth St. N.W., Washington, D.C. 20001.
Terms of Use and Privacy Statement.